FDA begins review of Actos drug injury reports
If you take Actos for diabetes, read this.
The Wall Street Journal (9/20, Dooren) reports that on Sept. 17, the Food and Drug Administration has begun a safety review of the Actos drug injury reports that have been made, examining possible links between longer term exposure to the drug and an increased risk for bladder cancer.“The agency said Friday that five-year results from an ongoing study show that patients who have taken Actos for the longest period of time had a higher risk of bladder cancer,” the AP (9/18, Perrone) reported. “Bladder cancer was also more prevalent in patients who had taken the largest cumulative dose of the drug.”
